分子バイオマーカーと診断のジャーナル

Hsa-miR-665, a microRNA molecule, has emerged as a promising biomarker with significant potential in the realm of cancer prognosis. This review explores the landscape of Hsa-miR-665 and its role as a prognostic indicator in various cancer types. By examining the latest research findings and its implications, this review underscores the significance of Hsa-miR-665 as a biomarker in predicting disease outcomes, aiding clinical decisionmaking and advancing personalized cancer care.

Autoimmune neuromuscular disorders encompass a diverse group of conditions that affect the peripheral nervous system and muscles. Early and accurate diagnosis of these disorders is often challenging, necessitating the exploration of contemporary approaches to biomarkers for improved clinical management. This review examines the landscape of biomarkers in autoimmune neuromuscular diseases, encompassing conditions such as myasthenia gravis, Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. The review delves into the role of molecular, genetic and immunological biomarkers in disease diagnosis, prognosis and therapeutic monitoring. By scrutinizing the latest advancements and their potential applications, we underscore the significance of contemporary biomarker strategies in advancing our understanding and management of autoimmune neuromuscular disorders.

The use of Extracellular Vesicles (EVs) has emerged as a promising approach in the diagnosis and treatment of chronic liver conditions. Chronic liver diseases, including cirrhosis, Non-Alcoholic Fatty Liver Disease (NAFLD) and viral hepatitis, present significant health challenges worldwide. EVs, such as exosomes and microvesicles, are membrane-bound particles released by various cell types, carrying a cargo of proteins, nucleic acids and lipids. This review explores the diagnostic and therapeutic potential of EVs in the context of chronic liver diseases. By highlighting the role of EVs in liver disease pathogenesis, biomarker discovery and their application in drug delivery, this review underscores the significant advancements and future possibilities of EV-based strategies in managing and understanding chronic liver conditions.

Idiopathic Pulmonary Fibrosis (IPF) is a progressive and debilitating lung disorder of unknown origin, posing significant diagnostic challenges. The role of biomarkers in understanding and managing this condition is pivotal. This literature review explores the landscape of molecular and genetic biomarkers in the context of IPF. It delves into the recent advances in the field, emphasizing the potential of these biomarkers in early diagnosis, disease progression monitoring and therapeutic advancements. The review underscores the significance of biomarkers in unraveling the intricate pathogenesis of IPF and in paving the way for more personalized and effective approaches to patient care.